Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.46 |
| ▸ | DRD3 | P35462 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorphenoxamine SCHEMBL29208 | 0.90 | CHRM2 (0.61) | CHRM2CYP2D6BLMKDM4EPOLB | |
| Embramine SCHEMBL28365 | 0.90 | CHRM2 (0.61) | CHRM2CYP2D6BLMKDM4EPOLB | |
| Chlorphenoxamine SCHEMBL125112 | 0.89 | CHRM2 (0.59) | CHRM2CYP2D6BLMKDM4EPOLB | |
| Embramine SCHEMBL1650532 | 0.89 | CHRM2 (0.59) | CHRM2CYP2D6BLMKDM4EPOLB | |
| Chlorphenoxamine SCHEMBL1649036 | 0.87 | CHRM2 (0.62) | CHRM2CYP2D6BLMKDM4EPOLB | |
| Doxylamine SCHEMBL12959067 | 0.84 | CHRM2 (1.00) | CHRM2CYP2D6BLMKDM4EPOLB | |
| Doxylamine SCHEMBL30116312 | 0.84 | CHRM2 (1.00) | CHRM2CYP2D6BLMKDM4EPOLB | |
| Doxylamine SCHEMBL4709 | 0.84 | CHRM2 (1.00) | CHRM2CYP2D6BLMKDM4EPOLB | |
| Doxylamine SCHEMBL30702275 | 0.84 | CHRM2 (1.00) | CHRM2CYP2D6BLMKDM4EPOLB | |
| Doxylamine SCHEMBL17047020 | 0.83 | CHRM2 (0.97) | CHRM2CYP2D6BLMKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 390 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2014186623-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF A CHAGAS DISEASE | BIOMED VALLEY DISCOVERIES (US) | 2014-11-20 | — | — | WO | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20050282879-A1 | Methods and composition for treatment of migraine and symptoms thereof | SALEHANI FOAD | 2005-12-22 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-12403094-B2 | Rheological solid oral composition | THE PROCTER & GAMBLE COMPANY (US) | 2025-09-02 | — | — | US | disclosed |
| US-12372536-B2 | Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof | PFIZER INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250032643-A1 | SYNTHETIC RECEPTORS | UCL BUSINESS LTD (GB) | 2025-01-30 | — | — | US | disclosed |
| US-20240425441-A9 | MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY | ICOSA PHARMA INC. (CA) | 2024-12-26 | — | — | US | disclosed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | disclosed |
| WO-1999025328-A1 | (+)-EPHEDRINE AS A SYMPATHOMIMETIC DRUG | WARNER-LAMBERT COMPANY (US) | 1999-05-27 | — | — | WO | disclosed |
| EP-0910410-A1 | TOPICAL COMPOSITION COMPRISING A COMBINATION OF ANTIHISTAMINIC COMPOUNDS WITH TERPENOID COMPOUNDS | Novartis Consumer Health S.A. (CH) | 1999-04-28 | — | — | EP | disclosed |
| WO-1998001134-A1 | ORAL PHARMACEUTICAL COMBINATIONS OF ANTIHISTAMINIC COMPOUNDS AND TERPENOIDS | NOVARTIS CONSUMER HEALTH S.A. (CH) | 1998-01-15 | — | — | WO | disclosed |
| WO-1998000168-A1 | TOPICAL COMPOSITION COMPRISING A COMBINATION OF ANTIHISTAMINIC COMPOUNDS WITH TERPENOID COMPOUNDS | NOVARTIS CONSUMER HEALTH S.A. (CH) | 1998-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282879-A1 | Methods and composition for treatment of migraine and symptoms thereof | HRH3, HRH4, HNMT | CHRM2 145/4885CYP2D6 785/4885BLM 1779/4885 |
| US-20240425441-A9 | MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY | ALOX12, ALOX15B, ALOX5 | CHRM2 1478/4885CYP2D6 312/4885BLM 3103/4885 |
| US-20250032643-A1 | SYNTHETIC RECEPTORS | GRM5, GRM3, GRM1 | CHRM2 241/4885CYP2D6 3455/4885BLM 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.